ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Retrovirus-Based Gene Therapy Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-18F16971
Home | Market Reports | Health| Health Conditions
Global Retrovirus Based Gene Therapy Drugs Market Research Report 2024
BUY CHAPTERS

Global Retrovirus-Based Gene Therapy Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-18F16971
Report
November 2025
Pages:116
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GSK
CHASELECTION
Molmed
GILD
Denovo Biopharma
Pfizer Inc
Epeius

Retrovirus-Based Gene Therapy Drugs Market

The global Retrovirus-Based Gene Therapy Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Retrovirus-based gene therapy drugs are drugs that use retroviruses as vectors to introduce normal or modified genes into patient cells to treat genetic diseases, cancer and other diseases. Retroviruses occur naturally in some animals and can reverse-transcribe RNA into DNA and insert into the genome of host cells. In gene therapy, scientists take advantage of this feature to load therapeutic genes into retroviral vectors, allowing them to enter the patient's cells and express the required proteins to achieve therapeutic purposes.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Retrovirus-Based Gene Therapy Drugs leading manufacturers including GSK, Chaselection, MolMed, GILD, Denovo Biopharma, Pfizer, Epeius, etc., dominate supply; the top five capture approximately % of global revenue, with GSK leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Retrovirus-Based Gene Therapy Drugs market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Retrovirus-Based Gene Therapy Drugs Market Report

Report Metric Details
Report Name Retrovirus-Based Gene Therapy Drugs Market
Segment by Type
  • CAR-T Therapy
  • Autologous CD34+ Cell Gene Therapy
Segment by Application
  • Hospital
  • Diagnostic and Testing Laboratories
  • Academic and Research Organizations
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company GSK, Chaselection, MolMed, GILD, Denovo Biopharma, Pfizer, Epeius
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Retrovirus-Based Gene Therapy Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Retrovirus-Based Gene Therapy Drugs Market report?

Ans: The main players in the Retrovirus-Based Gene Therapy Drugs Market are GSK, Chaselection, MolMed, GILD, Denovo Biopharma, Pfizer, Epeius

What are the Application segmentation covered in the Retrovirus-Based Gene Therapy Drugs Market report?

Ans: The Applications covered in the Retrovirus-Based Gene Therapy Drugs Market report are Hospital, Diagnostic and Testing Laboratories, Academic and Research Organizations, Others

What are the Type segmentation covered in the Retrovirus-Based Gene Therapy Drugs Market report?

Ans: The Types covered in the Retrovirus-Based Gene Therapy Drugs Market report are CAR-T Therapy, Autologous CD34+ Cell Gene Therapy

1 Study Coverage
1.1 Introduction to Retrovirus-Based Gene Therapy Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Retrovirus-Based Gene Therapy Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 CAR-T Therapy
1.2.3 Autologous CD34+ Cell Gene Therapy
1.3 Market Segmentation by Application
1.3.1 Global Retrovirus-Based Gene Therapy Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Diagnostic and Testing Laboratories
1.3.4 Academic and Research Organizations
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Retrovirus-Based Gene Therapy Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Retrovirus-Based Gene Therapy Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Retrovirus-Based Gene Therapy Drugs Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Retrovirus-Based Gene Therapy Drugs Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 CAR-T Therapy Market Size by Players
3.3.2 Autologous CD34+ Cell Gene Therapy Market Size by Players
3.4 Global Retrovirus-Based Gene Therapy Drugs Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Retrovirus-Based Gene Therapy Drugs Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Retrovirus-Based Gene Therapy Drugs Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Retrovirus-Based Gene Therapy Drugs Market Size by Type (2020-2031)
6.4 North America Retrovirus-Based Gene Therapy Drugs Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Retrovirus-Based Gene Therapy Drugs Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Retrovirus-Based Gene Therapy Drugs Market Size by Type (2020-2031)
7.4 Europe Retrovirus-Based Gene Therapy Drugs Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Retrovirus-Based Gene Therapy Drugs Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Retrovirus-Based Gene Therapy Drugs Market Size by Type (2020-2031)
8.4 Asia-Pacific Retrovirus-Based Gene Therapy Drugs Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Retrovirus-Based Gene Therapy Drugs Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Retrovirus-Based Gene Therapy Drugs Market Size by Type (2020-2031)
9.4 Central and South America Retrovirus-Based Gene Therapy Drugs Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Retrovirus-Based Gene Therapy Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Retrovirus-Based Gene Therapy Drugs Market Size by Type (2020-2031)
10.4 Middle East and Africa Retrovirus-Based Gene Therapy Drugs Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Retrovirus-Based Gene Therapy Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Business Overview
11.1.3 GSK Retrovirus-Based Gene Therapy Drugs Product Features and Attributes
11.1.4 GSK Retrovirus-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.1.5 GSK Retrovirus-Based Gene Therapy Drugs Revenue by Product in 2024
11.1.6 GSK Retrovirus-Based Gene Therapy Drugs Revenue by Application in 2024
11.1.7 GSK Retrovirus-Based Gene Therapy Drugs Revenue by Geographic Area in 2024
11.1.8 GSK Retrovirus-Based Gene Therapy Drugs SWOT Analysis
11.1.9 GSK Recent Developments
11.2 Chaselection
11.2.1 Chaselection Corporation Information
11.2.2 Chaselection Business Overview
11.2.3 Chaselection Retrovirus-Based Gene Therapy Drugs Product Features and Attributes
11.2.4 Chaselection Retrovirus-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.2.5 Chaselection Retrovirus-Based Gene Therapy Drugs Revenue by Product in 2024
11.2.6 Chaselection Retrovirus-Based Gene Therapy Drugs Revenue by Application in 2024
11.2.7 Chaselection Retrovirus-Based Gene Therapy Drugs Revenue by Geographic Area in 2024
11.2.8 Chaselection Retrovirus-Based Gene Therapy Drugs SWOT Analysis
11.2.9 Chaselection Recent Developments
11.3 MolMed
11.3.1 MolMed Corporation Information
11.3.2 MolMed Business Overview
11.3.3 MolMed Retrovirus-Based Gene Therapy Drugs Product Features and Attributes
11.3.4 MolMed Retrovirus-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.3.5 MolMed Retrovirus-Based Gene Therapy Drugs Revenue by Product in 2024
11.3.6 MolMed Retrovirus-Based Gene Therapy Drugs Revenue by Application in 2024
11.3.7 MolMed Retrovirus-Based Gene Therapy Drugs Revenue by Geographic Area in 2024
11.3.8 MolMed Retrovirus-Based Gene Therapy Drugs SWOT Analysis
11.3.9 MolMed Recent Developments
11.4 GILD
11.4.1 GILD Corporation Information
11.4.2 GILD Business Overview
11.4.3 GILD Retrovirus-Based Gene Therapy Drugs Product Features and Attributes
11.4.4 GILD Retrovirus-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.4.5 GILD Retrovirus-Based Gene Therapy Drugs Revenue by Product in 2024
11.4.6 GILD Retrovirus-Based Gene Therapy Drugs Revenue by Application in 2024
11.4.7 GILD Retrovirus-Based Gene Therapy Drugs Revenue by Geographic Area in 2024
11.4.8 GILD Retrovirus-Based Gene Therapy Drugs SWOT Analysis
11.4.9 GILD Recent Developments
11.5 Denovo Biopharma
11.5.1 Denovo Biopharma Corporation Information
11.5.2 Denovo Biopharma Business Overview
11.5.3 Denovo Biopharma Retrovirus-Based Gene Therapy Drugs Product Features and Attributes
11.5.4 Denovo Biopharma Retrovirus-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.5.5 Denovo Biopharma Retrovirus-Based Gene Therapy Drugs Revenue by Product in 2024
11.5.6 Denovo Biopharma Retrovirus-Based Gene Therapy Drugs Revenue by Application in 2024
11.5.7 Denovo Biopharma Retrovirus-Based Gene Therapy Drugs Revenue by Geographic Area in 2024
11.5.8 Denovo Biopharma Retrovirus-Based Gene Therapy Drugs SWOT Analysis
11.5.9 Denovo Biopharma Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Retrovirus-Based Gene Therapy Drugs Product Features and Attributes
11.6.4 Pfizer Retrovirus-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.6.5 Pfizer Recent Developments
11.7 Epeius
11.7.1 Epeius Corporation Information
11.7.2 Epeius Business Overview
11.7.3 Epeius Retrovirus-Based Gene Therapy Drugs Product Features and Attributes
11.7.4 Epeius Retrovirus-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.7.5 Epeius Recent Developments
12 Retrovirus-Based Gene Therapy DrugsIndustry Chain Analysis
12.1 Retrovirus-Based Gene Therapy Drugs Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Retrovirus-Based Gene Therapy Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Retrovirus-Based Gene Therapy Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
GSK
CHASELECTION
Molmed
GILD
Denovo Biopharma
Pfizer Inc
Epeius
List of Tables
 Table 1. Global Retrovirus-Based Gene Therapy Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Retrovirus-Based Gene Therapy Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Retrovirus-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Retrovirus-Based Gene Therapy Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Retrovirus-Based Gene Therapy Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Retrovirus-Based Gene Therapy Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Retrovirus-Based Gene Therapy Drugs Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Retrovirus-Based Gene Therapy Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Retrovirus-Based Gene Therapy Drugs as of 2024)
 Table 11. Global Retrovirus-Based Gene Therapy Drugs Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Retrovirus-Based Gene Therapy Drugs Companies Headquarters
 Table 13. Global Retrovirus-Based Gene Therapy Drugs Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Retrovirus-Based Gene Therapy Drugs Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Retrovirus-Based Gene Therapy Drugs Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Retrovirus-Based Gene Therapy Drugs Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Retrovirus-Based Gene Therapy Drugs Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Retrovirus-Based Gene Therapy Drugs High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Retrovirus-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
 Table 25. North America Retrovirus-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Retrovirus-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
 Table 27. Europe Retrovirus-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Retrovirus-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Retrovirus-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Retrovirus-Based Gene Therapy Drugs Investment Opportunities and Key Challenges
 Table 31. Central and South America Retrovirus-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Retrovirus-Based Gene Therapy Drugs Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Retrovirus-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. GSK Corporation Information
 Table 35. GSK Description and Major Businesses
 Table 36. GSK Product Features and Attributes
 Table 37. GSK Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. GSK Revenue Proportion by Product in 2024
 Table 39. GSK Revenue Proportion by Application in 2024
 Table 40. GSK Revenue Proportion by Geographic Area in 2024
 Table 41. GSK Retrovirus-Based Gene Therapy Drugs SWOT Analysis
 Table 42. GSK Recent Developments
 Table 43. Chaselection Corporation Information
 Table 44. Chaselection Description and Major Businesses
 Table 45. Chaselection Product Features and Attributes
 Table 46. Chaselection Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Chaselection Revenue Proportion by Product in 2024
 Table 48. Chaselection Revenue Proportion by Application in 2024
 Table 49. Chaselection Revenue Proportion by Geographic Area in 2024
 Table 50. Chaselection Retrovirus-Based Gene Therapy Drugs SWOT Analysis
 Table 51. Chaselection Recent Developments
 Table 52. MolMed Corporation Information
 Table 53. MolMed Description and Major Businesses
 Table 54. MolMed Product Features and Attributes
 Table 55. MolMed Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. MolMed Revenue Proportion by Product in 2024
 Table 57. MolMed Revenue Proportion by Application in 2024
 Table 58. MolMed Revenue Proportion by Geographic Area in 2024
 Table 59. MolMed Retrovirus-Based Gene Therapy Drugs SWOT Analysis
 Table 60. MolMed Recent Developments
 Table 61. GILD Corporation Information
 Table 62. GILD Description and Major Businesses
 Table 63. GILD Product Features and Attributes
 Table 64. GILD Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. GILD Revenue Proportion by Product in 2024
 Table 66. GILD Revenue Proportion by Application in 2024
 Table 67. GILD Revenue Proportion by Geographic Area in 2024
 Table 68. GILD Retrovirus-Based Gene Therapy Drugs SWOT Analysis
 Table 69. GILD Recent Developments
 Table 70. Denovo Biopharma Corporation Information
 Table 71. Denovo Biopharma Description and Major Businesses
 Table 72. Denovo Biopharma Product Features and Attributes
 Table 73. Denovo Biopharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Denovo Biopharma Revenue Proportion by Product in 2024
 Table 75. Denovo Biopharma Revenue Proportion by Application in 2024
 Table 76. Denovo Biopharma Revenue Proportion by Geographic Area in 2024
 Table 77. Denovo Biopharma Retrovirus-Based Gene Therapy Drugs SWOT Analysis
 Table 78. Denovo Biopharma Recent Developments
 Table 79. Pfizer Corporation Information
 Table 80. Pfizer Description and Major Businesses
 Table 81. Pfizer Product Features and Attributes
 Table 82. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Pfizer Recent Developments
 Table 84. Epeius Corporation Information
 Table 85. Epeius Description and Major Businesses
 Table 86. Epeius Product Features and Attributes
 Table 87. Epeius Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Epeius Recent Developments
 Table 89. Raw Materials Key Suppliers
 Table 90. Distributors List
 Table 91. Market Trends and Market Evolution
 Table 92. Market Drivers and Opportunities
 Table 93. Market Challenges, Risks, and Restraints
 Table 94. Research Programs/Design for This Report
 Table 95. Key Data Information from Secondary Sources
 Table 96. Key Data Information from Primary Sources


List of Figures
 Figure 1. Retrovirus-Based Gene Therapy Drugs Product Picture
 Figure 2. Global Retrovirus-Based Gene Therapy Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. CAR-T Therapy Product Picture
 Figure 4. Autologous CD34+ Cell Gene Therapy Product Picture
 Figure 5. Global Retrovirus-Based Gene Therapy Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Hospital
 Figure 7. Diagnostic and Testing Laboratories
 Figure 8. Academic and Research Organizations
 Figure 9. Others
 Figure 10. Retrovirus-Based Gene Therapy Drugs Report Years Considered
 Figure 11. Global Retrovirus-Based Gene Therapy Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Retrovirus-Based Gene Therapy Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Retrovirus-Based Gene Therapy Drugs Revenue Market Share by Region (2020-2031)
 Figure 15. Global Retrovirus-Based Gene Therapy Drugs Revenue Market Share Ranking (2024)
 Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 17. CAR-T Therapy Revenue Market Share by Player in 2024
 Figure 18. Autologous CD34+ Cell Gene Therapy Revenue Market Share by Player in 2024
 Figure 19. Global Retrovirus-Based Gene Therapy Drugs Revenue Market Share by Type (2020-2031)
 Figure 20. Global Retrovirus-Based Gene Therapy Drugs Revenue Market Share by Application (2020-2031)
 Figure 21. North America Retrovirus-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 22. North America Top 5 Players Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
 Figure 23. North America Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020 - 2031)
 Figure 24. North America Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 25. US Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 26. Canada Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 27. Mexico Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 28. Europe Retrovirus-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. Europe Top 5 Players Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
 Figure 30. Europe Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 31. Europe Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 32. Germany Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 33. France Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 34. U.K. Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 35. Italy Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 36. Russia Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific Retrovirus-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Top 8 Players Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
 Figure 39. Asia-Pacific Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Asia-Pacific Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 41. Indonesia Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 42. Japan Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 43. South Korea Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 44. Australia Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 45. India Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 46. Indonesia Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 47. Vietnam Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 48. Malaysia Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 49. Philippines Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 50. Singapore Retrovirus-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 51. Central and South America Retrovirus-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 52. Central and South America Top 5 Players Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
 Figure 53. Central and South America Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 54. Central and South America Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 55. Brazil Retrovirus-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 56. Argentina Retrovirus-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 57. Middle East and Africa Retrovirus-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 58. Middle East and Africa Top 5 Players Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
 Figure 59. South America Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 60. Middle East and Africa Retrovirus-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 61. GCC Countries Retrovirus-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 62. Israel Retrovirus-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 63. Egypt Retrovirus-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 64. South Africa Retrovirus-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 65. Retrovirus-Based Gene Therapy Drugs Industry Chain Mapping
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Viral Vector Based Gene Therapy Drugs Market Research Report 2024
Global AAV Vector Based Gene Therapy Drugs Market Research Report 2024
Gene Therapy based Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drug Based on Gene Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global AAV Gene Therapy Drugs Market Research Report 2024
Global Gene Therapy Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031
Global Nucleic Acid Based Gene Therapy Market Research Report 2025
Global Gene Therapies for Cancer Treatment Market Research Report 2024
Global Gene based Therapy Medicinal Market Research Report 2024
Gene based Advanced Therapy Medical Product Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Retroviral Vectors Market Research Report 2024
Global Gene based Advanced Therapy Medicinal Market Research Report 2025
Global Viral Vectors Gene Therapy Market Research Report 2025
Global RNA based Therapeutics Drug Market Research Report 2024
Drugs Based on Gene Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global LV Based Cell and Gene Therapy Products Market Research Report 2024
Global AAV based Gene Therapy Products Market Research Report 2024
Global Nucleic Acid based Therapy Market Research Report 2024
Global Nucleic acid based Therapeutics Drug Market Research Report 2024
Global Cell and Gene Therapy Market Research Report 2024

RELATED REPORTS

Global Coronary Imaging Catheter Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32P14840
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Digital Platform for Chronic Kidney Disease (CKD) Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-20V18395
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Continuous Glucose Monitoring Sensor Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32G20014
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9U20281
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions